Background Myocardial damage in myocarditis is mediated, in part, by immunological mechanisms. High-dose intravenous y-globulin (IVIG) is an immunomodulatory agent that is beneficial in myocarditis secondary to Kawasaki disease, as well as in murine myocarditis. Since 1990, the routine management of presumed acute myocarditis at Children's Hospital, Boston, and Children's Hospital, Los Angeles,...

Background This study aimed to evaluate the effectiveness of Intravenous immunoglobulin (IVIg) and combination of IVIg and Methylprednisolone for childhood Idiopathic (autoimmune) Thrombocytopenia (ITP) treatment; in addition investigate the related factors to develop chronic form of under 15 years ITP. Materials and Methods This retrospective study conducted on 88 ITP patients that treated wit...

OBJECTIVE To evaluate the effect of high-dose intravenous immunoglobulin (IVIG) in toxic epidermal necrolysis (TEN), parameters that may affect response to treatment, and the effect of different IVIG batches on Fas-mediated cell death. DESIGN Multicenter retrospective analysis of 48 consecutive TEN patients treated with IVIG. SETTING Fourteen university hospital dermatology centers in Europ...

not received. [12.30–12.50] B cell superantigen-like interaction of a subset of IVIG with phage-displayed human IgG and IgM originating from VH germ-line segments 3-23 and 3-30/3-30.5 Peter Fischer, Stephan Leucht, Awuku Osei, Melanie Hoffmann, Nina Jendreyko, Heike Lerch, Martina M. Uttenreuther-Fischer, Gerhard Gaedicke Laboratory of Molecular Biology, Charité Children’s Hospital, OHC, Humbol...

Though the indication mentioned for resorting to plasmapheresis in the report is the unaffordability of intravenous immunoglobulin (IVIG) therapy, I wish to highlight other important reasons for preferring plasmapheresis over IVIG. Firstly, IVIG is known to exert its immunomodulatory effects for a prolonged period of time. The mean duration of action of IVIG is 53 days and the half life of immu...

Background High-dose IVIG (2 g/kg) alone or low-dose IVIG (100 mg/kg) in conjunction with plasma exchange is typically administered as a renal transplantation desensitization therapy. Herein, we monitored changes in T cell and B cell flow cytometry crossmatch (FCXM) to assess the effects of short-term super high-dose IVIG (4 g/kg) administration with plasmapheresis before living-donor renal tra...

BACKGROUND Intravenous immunoglobulin (IVIG) is the treatment of choice in Kawasaki disease (KD). IVIG is used to prevent cardiovascular complications related to KD. However, a proportion of KD patients have persistent fever after IVIG treatment and are defined as IVIG resistant. METHODS AND RESULTS To develop a risk scoring system based on genetic markers to predict IVIG responsiveness in KD...

OBJECTIVE The objective of this study is to evaluate the economic benefits of immunoglobulin replacement therapy achieved subcutaneously (subcutaneous immunoglobulin, SCIG) by the rapid push method compared to intravenous infusion therapy (intravenous immunoglobulin, IVIG) in primary immune deficiency (PID) patients from the healthcare system perspective in the context of the adult SCIG home in...